Reimbursed Care Access in Gabon

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. Relevant punitive and regulatory provisions regarding possession/use of substances listed as stupéfiants are set out in the Gabonese Penal Code (Code pénal, Loi n° 042/2018 du 04/07/2019). #

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. #

Esketamine (pharmaceutical Spravato/other esketamine products) is not documented as having a national marketing‑authorization, public reimbursement or a formalized access pathway in Gabon. Gabonese law provides exemptions for medical practice/healthcare professionals for the use of controlled substances in treatment contexts, but there is no public evidence of esketamine registration, national clinical‑use guidance, or reimbursement listing in Gabonese regulatory sources. For the general rule on controlled substances and medical exceptions see the Gabonese Penal Code (Loi n° 042/2018 du 04/07/2019). #

Ketamine is used in Gabon as an established anaesthetic agent in hospitals and emergency care; published clinical/audit reports from Gabonese hospitals describe routine clinical use of ketamine for induction and anaesthetic management (e.g., usage reported as the most used hypnotic agent in a Libreville hospital audit). This reflects the standard worldwide practice that permits controlled medical use of ketamine under the supervision of licensed clinicians. #

Regulatory context: Gabon’s Penal Code criminalizes illicit possession and trafficking of stupéfiants but explicitly contemplates medical treatment/supervision exemptions and the ability for courts to mandate medical surveillance or detoxification where illicit use is connected to health needs (Code pénal, Loi n° 042/2018 du 04/07/2019). That framework allows licensed medical practitioners and hospitals to use controlled anaesthetics (including ketamine) in clinical care, but there is no public evidence of a formal national reimbursement schedule for psychiatric uses of ketamine (off‑label) or of routine public insurance coverage for ketamine‑based psychiatric treatment. #

Practical reimbursement/access: Available data indicate ketamine is used in public hospital anaesthesia settings (clinical practice), not within any documented nationally reimbursed psychedelic‑assisted psychiatric program. There is no public record of ketamine for psychiatric indications being formally included in Gabonese national health reimbursement lists or clinical practice guidelines.

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. #

The iboga plant (Tabernanthe iboga) and related products are subject to specific cultural‑protection and export controls in Gabon: the Gabonese authorities have applied export restrictions and cultural protection measures for iboga, and export authorisation is handled via ministries responsible for culture/forestry. In 2019 reporting and community engagement summaries noted that Gabon suspended or highly restricted commercial export of wild‑harvested iboga and that export permits require approval (no broad export authorisations were being granted at that time). This creates a regulated, protectionist regime for iboga/ibogaine rather than an open medical/reimbursement pathway. #

Because iboga/ibogaine are not documented as approved pharmaceutical products in Gabon and are governed by cultural/forestry export controls, there is no national reimbursement pathway for ibogaine treatment; use outside traditional/cultural contexts or approved research would be constrained by export/possession controls and by general narcotics provisions in the Penal Code. #

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. (Use of DMT‑containing preparations such as ayahuasca would be covered by the same national prohibitions on psychotropic/stupéfiant substances.) #

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. (Peyote and synthetic mescaline fall under the stupéfiants framework.) #

Currently classified as a strictly controlled substance under national drug‑scheduling provisions in the Gabonese Penal Code, with no authorized medical use outside of approved clinical research. Novel phenethylamines (2C‑series) would be treated as prohibited psychotropic/stupéfiant substances under Gabonese narcotics law. #